The frequency of PBRM1 mutation was similar between patients with aggressive and non-aggressive ccRCC, perhaps because it is an early, essential event in tumorigenesis that does not impact clinical outcome, but instead plays a principal role in tumor initiation. Here, PBRM1 is linked to neoplasm.